Institutional dossier
The documented history of Genentech: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2021 to 2023-11-21 · 0 undated
3 claims · 3 sources · 3 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: A member of the Roche Group.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
Connected institutional dossiers
Institutions linked by a documented relationship. Each keeps its own chronology and evidence. When units combine, their earlier records stay separate.
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2021Record year · 1 claims
- Roche’s Annual Report 2021 states that Genentech “recently acquired Prescient Design”; a Genentech story of 2 November 2021 states that the Prescient Design team joined Genentech in August 2021 as a new department.Genentech → acquired → Prescient DesignInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
Roche’s and Genentech’s own accounts; no price, terms or closing date are stated (maintainer decision of 2026-10-30, after the cross-family check located the annual report). The Genentech story is recorded by paraphrase because its text is carried in script data that the quotation check cannot read.
Year of the acquisition as Roche’s Annual Report 2021 reports it (“recently acquired”); no closing date is stated. Genentech’s story dates the team’s joining to August 2021, which is not a documented closing date.
2023Record year · 2 claims
- Genentech announced on 21 November 2023 a multi-year strategic research collaboration with NVIDIA to accelerate and optimize Genentech's machine-learning algorithms and models on NVIDIA DGX Cloud, including NVIDIA BioNeMo.Genentech → announced a partnership with → NVIDIAInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
An announced collaboration; no financial terms are stated, and the record does not establish outputs. The release states that NVIDIA will not have direct access to Genentech's proprietary data unless granted.
Date of Genentech's press release.
- Genentech's release of 21 November 2023 names Aviv Regev as EVP and head of Genentech Research and Early Development (gRED).Aviv Regev → held role at → GenentechInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A historical role snapshot; neither the start nor the end of the role is established.
The date identifies this documented announcement or publication; it does not establish a continuing state.